Natural Products against Human and Veterinary Trichomonads: From In Vitro Activity to Future Therapeutic Perspectives
- 1Universidade Federal do Rio Grande do Sul , , , ,
Abstract
Pathogenic trichomonads are flagellated protozoan parasites of the urogenital and digestive tracts of humans and animals. These organisms impose substantial health and economic burdens on the world. Trichomonas vaginalis causes human urogenital trichomoniasis, the most common nonviral sexually transmitted infection worldwide, and has been associated with adverse reproductive outcomes and increased risk of HIV transmission. In animals, Trichomonas gallinae causes avian trichomoniasis, a disease of the upper digestive tract that may impair feeding, compromise survival, and contribute to bird population declines, whereas Tritrichomonas foetus is responsible for bovine trichomoniasis, a major cause of cattle production losses. Despite their importance, therapeutic options remain limited. Human and avian trichomoniasis still rely on 5-nitroimidazoles, but drug resistance and regulatory restrictions have become important concerns, whereas no approved pharmacological treatment is currently available for bovine trichomoniasis, and infected animals are culled. In this context, natural products have emerged as valuable sources of new antitrichomonal agents. This Review summarizes 84 studies published between 2016 and 2026 investigating natural products against T. vaginalis, T. gallinae, and T. foetus, including plant-derived extracts and fractions, essential oils, isolated compounds, microbial metabolites, and nanotechnology-based formulations. Although several products displayed relevant antitrichomonal activity, most evidence remains restricted to in vitro studies, with comparatively few in vivo evaluations and no clinical validation of natural-product-derived candidates for trichomoniasis. Overall, natural products represent a chemically diverse and still underexplored source of antitrichomonal leads, but further validation of their selectivity, pharmacological properties, and in vivo efficacy is required before their therapeutic potential can be established.
Related
- Valorisation of Insect Farming By-Products into Chitosan: Chemical Characterisation and Bioactivity for Veterinary Use
- Characterization and evaluation of the anti-streptococcal activity of a novel zoocin A-like endopeptidase for potential veterinary applications
- Formulation, stability, and delivery of bacteriophage cocktails in veterinary medicine: a review of physicochemical constraints and therapeutic outcomes in production animals
- Bee-Derived Products in Neurodegenerative Diseases: Bioactive Constituents, Redox-Modulating Mechanisms, Evidence, and Translational Perspectives
- Therapeutic cancer vaccines: development, challenges, and future perspectives
BibTeX
@article{soares2026natural,
title = {{Natural Products against Human and Veterinary Trichomonads: From In Vitro Activity to Future Therapeutic Perspectives}},
author = {Bárbara B. R. Soares and Saulo A. Menezes and Tiana Tasca},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c08481},
url = {https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c08481/5453948/Natural-Products-against-Human-and-Veterinary},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Natural Products against Human and Veterinary Trichomonads: From In Vitro Activity to Future Therapeutic Perspectives
AU - Bárbara B. R. Soares
AU - Saulo A. Menezes
AU - Tiana Tasca
PY - 2026
DA - 2026/10/19
JO - ACS Omega
DO - 10.1021/acsomega.6c08481
UR - https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c08481/5453948/Natural-Products-against-Human-and-Veterinary
AB - Pathogenic trichomonads are flagellated protozoan parasites of the urogenital and digestive tracts of humans and animals. These organisms impose substantial health and economic burdens on the world. Trichomonas vaginalis causes human urogenital trichomoniasis, the most common nonviral sexually transmitted infection worldwide, and has been associated with adverse reproductive outcomes and increased risk of HIV transmission. In animals, Trichomonas gallinae causes avian trichomoniasis, a disease of the upper digestive tract that may impair feeding, compromise survival, and contribute to bird population declines, whereas Tritrichomonas foetus is responsible for bovine trichomoniasis, a major cause of cattle production losses. Despite their importance, therapeutic options remain limited. Human and avian trichomoniasis still rely on 5-nitroimidazoles, but drug resistance and regulatory restrictions have become important concerns, whereas no approved pharmacological treatment is currently available for bovine trichomoniasis, and infected animals are culled. In this context, natural products have emerged as valuable sources of new antitrichomonal agents. This Review summarizes 84 studies published between 2016 and 2026 investigating natural products against T. vaginalis, T. gallinae, and T. foetus, including plant-derived extracts and fractions, essential oils, isolated compounds, microbial metabolites, and nanotechnology-based formulations. Although several products displayed relevant antitrichomonal activity, most evidence remains restricted to in vitro studies, with comparatively few in vivo evaluations and no clinical validation of natural-product-derived candidates for trichomoniasis. Overall, natural products represent a chemically diverse and still underexplored source of antitrichomonal leads, but further validation of their selectivity, pharmacological properties, and in vivo efficacy is required before their therapeutic potential can be established.
SN - 2470-1343
ER -